Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Microsoft
MSFT
|
+$351M |
| 2 |
Netflix
NFLX
|
+$343M |
| 3 |
Berkshire Hathaway Class A
BRK.A
|
+$293M |
| 4 |
Nike
NKE
|
+$186M |
| 5 |
Delta Air Lines
DAL
|
+$177M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$1.33B |
| 2 |
Tesla
TSLA
|
+$344M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$306M |
| 4 |
NVIDIA
NVDA
|
+$281M |
| 5 |
Boeing
BA
|
+$251M |
Sector Composition
| 1 | Technology | 19.27% |
| 2 | Healthcare | 18.45% |
| 3 | Consumer Discretionary | 12.35% |
| 4 | Consumer Staples | 10.15% |
| 5 | Industrials | 9.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTH
3201
DELISTED
Genetron Holdings Limited ADS
GTH
| $124K | ﹤0.01% |
50,700
-133
| -0.3% | -$325 |
|
3202
Alset
AEI
$146M
| $123K | ﹤0.01% |
92,966
-100
| -0.1% | -$132 |
|
|
TMQ
3203
Trilogy Metals
TMQ
$351M
| $123K | ﹤0.01% |
251,500
-65,800
| -21% | -$32.2K |
|
3204
Tonix Pharmaceuticals
TNXP
$274M
| $122K | ﹤0.01% |
70
+4
| +6% | +$6.97K |
|
|
CYAN
3205
DELISTED
Cyanotech Corp
CYAN
| $122K | ﹤0.01% |
152,209
-2,300
| -1% | -$1.84K |
|
3206
Celularity
CELU
$62.7M
| $121K | ﹤0.01% |
54,340
+26,899
| +98% | +$59.9K |
|
3207
LiveWire
LVWR
$927M
| $121K | ﹤0.01% |
+17,502
| New | +$121K |
|
3208
Skillsoft
SKIL
$117M
| $121K | ﹤0.01% |
6,810
+2,620
| +63% | +$46.6K |
|
3209
Aura Biosciences
AURA
$400M
| $121K | ﹤0.01% |
13,500
-6,000
| -31% | -$53.8K |
|
|
BRAG
3210
Bragg Gaming Group
BRAG
$66.2M
| $120K | ﹤0.01% |
24,600
+8,200
| +50% | +$40K |
|
3211
5E Advanced Materials
FEAM
$91.6M
| $120K | ﹤0.01% |
2,300
-2,513
| -52% | -$131K |
|
|
HIVE
3212
HIVE Digital Technologies
HIVE
$776M
| $120K | ﹤0.01% |
39,020
-314,480
| -89% | -$967K |
|
3213
Advent Technologies
ADN
$8.22M
| $118K | ﹤0.01% |
10,070
-8,400
| -45% | -$98.4K |
|
3214
Definitive Healthcare
DH
$414M
| $118K | ﹤0.01% |
+14,800
| New | +$118K |
|
3215
HeartCore Enterprises
HTCR
$23.5M
| $118K | ﹤0.01% |
119,194
-8,366
| -7% | -$8.28K |
|
3216
Oramed Pharmaceuticals
ORMP
$95.5M
| $116K | ﹤0.01% |
44,300
+10,600
| +31% | +$27.8K |
|
|
HITI
3217
High Tide
HITI
$294M
| $115K | ﹤0.01% |
62,200
+38,587
| +163% | +$71.3K |
|
3218
Gray Media, Inc. Class A
GTN.A
$1.02B
| $114K | ﹤0.01% |
15,200
+300
| +2% | +$2.25K |
|
3219
IZEA Worldwide
IZEA
$63.1M
| $114K | ﹤0.01% |
52,503
+6,478
| +14% | +$14.1K |
|
|
PVLA
3220
Palvella Therapeutics, Inc. Common Stock
PVLA
$661M
| $114K | ﹤0.01% |
4,766
+147
| +3% | +$3.52K |
|
|
FRLN
3221
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $113K | ﹤0.01% |
26,360
+4,500
| +21% | +$19.3K |
|
|
VOXR
3222
Vox Royalty Corp
VOXR
$178M
| $112K | ﹤0.01% |
55,400
+42,200
| +320% | +$85.3K |
|
|
ZEPP
3223
Zepp Health
ZEPP
$744M
| $112K | ﹤0.01% |
24,300
-250
| -1% | -$1.15K |
|
|
SHCR
3224
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $111K | ﹤0.01% |
+118,100
| New | +$111K |
|
3225
Rani Therapeutics
RANI
$23.3M
| $111K | ﹤0.01% |
51,000
-37,201
| -42% | -$81K |
|